MetaCap

Chemomab Therapeutics (CMMB) vs Radiopharm Theranostics (RADX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Chemomab Therapeutics (CMMB) has outperformed Radiopharm Theranostics (RADX) over the past year, losing 53.0% versus a loss of 86.1%. Radiopharm Theranostics is the larger company by market cap ($9.9 million vs $9.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CMMB-52.96%RADX-86.15%
+145%+24%-97%
Nov 21, 20251 yearNov 20, 2026
CMMB-82.40%RADX-96.66%
+33%-35%-103%
Dec 2, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CMMB versus RADX key metrics
MetricCMMBRADX
Share price$1.19$0.6304
Market cap$9.58M$9.90M
1-day change+4.39%-9.71%
YTD return-27.88%-87.92%
1-year return-52.96%-86.15%
5-year return-96.65%—
EPS (TTM)$-1.04$-3.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$3.63M
Revenue growth (YoY)—+1114.27%
Net income (latest FY)$-8.99M$-38.34M
Gross margin—1.08%
Operating margin—-1050.63%
Net margin—-1055.27%
52-week high$2.99$16.25
52-week low$0.92$0.63
Distance from 52-week high-60.20%-96.12%
Analyst consensusnonestrong_buy
Avg. price target upside+320.17%+2595.11%
Average volume102.39K55.23K
Shares outstanding8.05M15.70M
Employees—14
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CMMB has outperformed RADX by 33.2 percentage points over the past year.

About Chemomab Therapeutics

CMMB stock →

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.

Health Care · Biotechnology: Pharmaceutical Preparations

About Radiopharm Theranostics

RADX stock →

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

CMMB vs RADX FAQ

Which is bigger, Chemomab Therapeutics or Radiopharm Theranostics?

Radiopharm Theranostics (RADX) is larger, with a market capitalization of $9.90M compared with $9.58M for Chemomab Therapeutics (CMMB).

Which stock has performed better over the past year, CMMB or RADX?

CMMB returned -52.96% over the past 12 months, compared with -86.15% for RADX (price return, excluding dividends). Past performance does not predict future results.

Are Chemomab Therapeutics and Radiopharm Theranostics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons